mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial

mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial

Abstract Background High-risk stage III colon cancer has a considerably poorer prognosis than stage II and low-risk stage III colon cancers. Nevertheless, most guidelines recommend similar adjuvant treatment approaches for all these stages despite the dearth of research focusing on high-risk stage I...

Full description

Bibliographic Details
Main Authors: Kyung-Ha Lee, In Jun Yang, Gi Won Ha, Jaeim Lee, Youn Young Park, Suk Hwan Lee, Jong Min Lee, Jung Hoon Bae, Eun Jung Park, Hyungjin Kim, Keun Young Kim, Sanghyung An, Ik Yong Kim, Ji Yeon Kim
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
High-risk stage III colon cancer
Adjuvant chemotherapy
mFOLFIRINOX
mFOLFOX 6
Prognosis
Efficacy
Online Access:https://doi.org/10.1186/s12885-024-11939-x

Internet

https://doi.org/10.1186/s12885-024-11939-x

Similar Items